US FDA Approves Niraparib and Abiraterone Acetate, the First-And-Only Dual Action Tablet for the Treatment of Patients With BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Recommended
US FDA Approves Niraparib and Abiraterone Acetate, the First-And-Only Dual Action Tablet for the Treatment of Patients With BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Based on results from the phase 3, MAGNITUDE study, the FDA has approved niraparib and abiraterone acetate plus prednisone for patients with deleterious or suspected deleterious BRCA-positive mCRPC.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->